Progenics Pharmaceuticals Inc. (PGNX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
ONE WORLD TRADE CENTER NEW YORK, NY 10007 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 42,049 | 64,493 | 84,823 | 109,587 | 137,686 | 148,851 | |||
| Cash and cash equivalents | 42,049 | 64,493 | 84,823 | 109,587 | 137,686 | 148,851 | |||
| Receivables | 15,976 | 6,174 | 10,569 | 4,935 | 3,803 | 5,821 | |||
| Other current assets | 5,707 | 5,136 | 4,806 | 3,125 | 2,640 | 2,237 | |||
| Total current assets: | 63,732 | 75,803 | 100,198 | 117,647 | 144,129 | 156,909 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 13,493 | 13,681 | 13,889 | 13,293 | ✕ | ✕ | |||
| Property, plant and equipment | 11,688 | 9,254 | 7,008 | 6,062 | 3,944 | 3,977 | |||
| Intangible assets, net (including goodwill) | 24,670 | 24,946 | 25,222 | 25,498 | 19,740 | 19,967 | |||
| Goodwill | 17,847 | 17,847 | 17,847 | 17,847 | 13,074 | 13,074 | |||
| Intangible assets, net (excluding goodwill) | 6,823 | 7,099 | 7,375 | 7,651 | 6,666 | 6,893 | |||
| Restricted cash and investments | 1,529 | ||||||||
| Other noncurrent assets | 5,887 | 6,368 | 6,464 | 1,704 | 1,684 | ||||
| Total noncurrent assets: | 55,738 | 54,249 | 52,583 | 46,557 | 25,368 | 25,473 | |||
| TOTAL ASSETS: | 119,470 | 130,052 | 152,781 | 164,204 | 169,497 | 182,382 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 14,352 | 13,135 | 17,210 | 10,068 | 10,977 | 8,279 | |||
| Accounts payable | 1,249 | 674 | 272 | 564 | 444 | 629 | |||
| Accrued liabilities | 13,103 | 12,461 | 16,938 | 9,504 | 10,533 | 7,650 | |||
| Debt | 7,716 | 7,009 | 6,361 | 6,478 | 5,419 | 8,216 | |||
| Business combination, contingent consideration, liability | 7,900 | 7,050 | |||||||
| Other undisclosed current liabilities | |||||||||
| Total current liabilities: | 22,068 | 20,144 | 23,571 | 24,446 | 23,446 | 16,495 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 46,915 | 49,643 | 51,654 | 52,355 | 39,180 | 38,332 | |||
| Long-term debt, excluding current maturities | 31,910 | 34,489 | 36,342 | 37,568 | 39,180 | 38,332 | |||
| Liabilities, other than long-term debt | 3,934 | 4,300 | 4,800 | 4,000 | 5,768 | 12,646 | |||
| Deferred income tax liabilities | 34 | ✕ | ✕ | ||||||
| Other liabilities | 1,818 | 1,746 | |||||||
| Operating lease, liability | 15,005 | 15,154 | 15,312 | 14,787 | ✕ | ✕ | |||
| Business combination, contingent consideration, liability | 3,900 | 4,300 | 4,800 | 4,000 | 3,950 | 10,900 | |||
| Other undisclosed noncurrent liabilities | 28 | 28 | 28 | 28 | 26 | ||||
| Total noncurrent liabilities: | 50,849 | 53,971 | 56,482 | 56,383 | 44,976 | 51,004 | |||
| Total liabilities: | 72,917 | 74,115 | 80,053 | 80,829 | 68,422 | 67,499 | |||
| Equity | |||||||||
| Equity, attributable to parent | 46,553 | 55,937 | 72,728 | 83,375 | 101,075 | 114,883 | |||
| Common stock | 113 | 112 | 112 | 110 | 110 | 110 | |||
| Treasury stock, value | (2,741) | (2,741) | (2,741) | (2,741) | (2,741) | (2,741) | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (933) | ||||||||
| Additional paid in capital | 727,089 | 725,356 | 724,027 | 714,096 | 713,019 | 712,111 | |||
| Accumulated other comprehensive loss | (148) | (305) | (94) | (147) | (105) | (93) | |||
| Accumulated deficit | (677,760) | (666,485) | (647,643) | (627,943) | (609,208) | (594,504) | |||
| Total equity: | 46,553 | 55,937 | 72,728 | 83,375 | 101,075 | 114,883 | |||
| TOTAL LIABILITIES AND EQUITY: | 119,470 | 130,052 | 152,781 | 164,204 | 169,497 | 182,382 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 15,126 | 5,613 | 9,966 | 4,281 | 3,238 | 5,317 | ||
| Cost of revenue | (958) | (1,317) | (493) | |||||
| Cost of goods and services sold | (1,358) | (1,317) | (493) | |||||
| Gross profit: | 14,168 | 4,296 | 9,473 | 4,281 | 3,238 | 5,317 | ||
| Operating expenses | (24,883) | (22,912) | (29,059) | (22,516) | (17,790) | (30,365) | ||
| Other undisclosed operating income | 500 | 493 | ||||||
| Operating loss: | (10,715) | (18,116) | (19,093) | (18,235) | (14,552) | (25,048) | ||
| Nonoperating expense | (543) | (726) | (607) | (500) | (235) | (762) | ||
| Loss from continuing operations before income taxes: | (11,258) | (18,842) | (19,700) | (18,735) | (14,787) | (25,810) | ||
| Income tax benefit | 83 | 1,453 | ||||||
| Other undisclosed loss from continuing operations | (17) | |||||||
| Loss from continuing operations: | (11,275) | (18,842) | (19,700) | (18,735) | (14,704) | (24,357) | ||
| Loss before gain (loss) on sale of properties: | (11,275) | (18,842) | (19,700) | (18,735) | (14,704) | (24,357) | ||
| Net loss available to common stockholders, diluted: | (11,275) | (18,842) | (19,700) | (18,735) | (14,704) | (24,357) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (11,275) | (18,842) | (19,700) | (18,735) | (14,704) | (24,357) | ||
| Other undisclosed comprehensive loss | (72) | |||||||
| Comprehensive loss: | (11,275) | (18,842) | (19,700) | (18,735) | (14,776) | (24,357) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 157 | (211) | 53 | (42) | 60 | (4) | ||
| Comprehensive loss, net of tax, attributable to parent: | (11,118) | (19,053) | (19,647) | (18,777) | (14,716) | (24,361) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.